ORTEC mentioned as a Representative Vendor in 2026 Gartner® Market Guide for Vehicle Routing and Scheduling

ORTEC advances AI-powered planning for more adaptive, resilient logistics operations.

ZOETERMEER, Netherlands, Oct. 7, 2026 /PRNewswire/ -- ORTEC, a global leader in planning and decision-support software, today announced it has been mentioned as a Representative Vendor in the 2026 Gartner® Market Guide for Vehicle Routing and Scheduling (VRS). We hold the view that this recognition comes at a time when logistics organizations are facing growing operational complexity, increasing sustainability requirements and rising customer expectations, while simultaneously exploring how AI can improve planning, decision-making and execution.

For ORTEC, inclusion in the Market Guide underscores the company's continued investment in enabling organizations to move beyond traditional route optimization toward more intelligent, and adaptive logistics operations. As businesses seek solutions that can respond dynamically to disruptions, capacity constraints and changing delivery environments, ORTEC believes its combination of advanced optimization, logistics expertise and AI-powered decision support is uniquely positioned to help customers create lasting business value.

"We are proud to be recognized as a Representative Vendor in the 2026 Gartner Market Guide for Vehicle Routing and Scheduling," said Georgios Sarigiannidis, CEO of ORTEC. "We feel this reflects both the trust our customers place in us and the technology and expertise we have built over decades. Logistics operations are becoming increasingly complex. Organizations do not need more dashboards, alerts, or decisions. They need trusted systems that remove operational noise, automate what can be automated, and help people focus on what truly matters. By combining optimization, AI, and deep logistics expertise, ORTEC helps organizations build more resilient, efficient, and adaptable operations. We believe Gartner's recognition reinforces the direction we have chosen and the value we continue to deliver to customers every day".

Gartner defines a vehicle routing and scheduling (VRS) solution as "an application that creates vehicle routes and schedules, considering multiple constraints and service requirements while minimizing transportation fleet costs and mileage." Gartner's research notes that "The interest in VRS applications continues to grow, fueled by continued challenges resulting from supply chain disruptions, government regulations on emissions and expansion of various delivery models."

Among its key findings, Gartner reports that the influence of AI is being reflected in the VRS market: "AI is having a significant impact on VRS vendor roadmaps, transforming it from a feature enhancement into a core strategic mandate for future development," with most vendors already exploring AI agents and generative AI to support roles including dispatchers, planners, drivers, and customer support.

For our customers, partners, and prospective clients, we believe ORTEC's inclusion in the Market Guide reflects the company's expertise, market relevance, and commitment to AI driven innovation. In a rapidly evolving logistics landscape, organizations require partners they can rely on to navigate complexity, drive performance and embrace emerging technologies with confidence.

The 2026 Gartner Market Guide for Vehicle Routing and Scheduling is available on Gartner's website to Gartner subscribers.

Gartner Disclaimer

Gartner, Market Guide for Vehicle Routing and Scheduling, Nathan Lease, Zee Zakaria,, 17 July 2026

GARTNER is a trademark of Gartner, Inc. and/or its affiliates. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner's business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About ORTEC

ORTEC is a global provider of AI-powered supply chain planning, logistics optimization and workforce management software. Since 1981, ORTEC has helped organizations across industries transform operational complexity into better decisions, more efficient use of resources and stronger business performance. With customers around the world and an international presence spanning Europe, North America, Latin America, Asia-Pacific and beyond, ORTEC combines deep optimization expertise with practical AI to help organizations adapt to change and make work flow.

SOURCE ORTEC

Share this article

A New Financial Wellness Think Tank™ report, "Build or Buy," estimates an in-house program costs between $21 million to $38 million and more than a decade of time; finds expertise, not budget, is the biggest barrier.

EL SEGUNDO, Calif., Oct. 7, 2026 /PRNewswire/ -- Most large employers have settled the question of whether to offer a financial wellness program. The open question now is how to source it. Among those with a financial wellness strategy or developing one, 87% had outside help building it, and the share relying on a dedicated financial wellness vendor rose from 47% in 2020 to 66% in 2025, according to the Employee Benefit Research Institute (EBRI). A new white paper from Financial Finesse's Financial Wellness Think Tank™ examines why and estimates what building a program from scratch would take: $21 million to $38 million in product and content development alone, on a timeline longer than most benefits plans anticipate.

"The data is crystal clear," said Liz Davidson, founder and CEO of Financial Finesse. "When nearly nine in ten employers with a financial wellness strategy rely on outside expertise, it tells us something important: financial wellness is not just a technology challenge. It's a specialized discipline that combines personal finance, behavior change, coaching and compliance. Most organizations recognize it's more effective to partner for that expertise than spend years trying to recreate it."

The report, Build or Buy: What It Costs to Create a Financial Wellness Benefit, draws on the disclosed venture funding and acquisitions across workplace financial wellness providers, published software R&D benchmarks, economic research on what it costs to copy an established product, and EBRI's latest Financial Wellbeing Employer Survey. Most employers, the EBRI data shows, don't hand the work off entirely: 59% said their own company was also involved. The trend is toward adding outside expertise, not replacing internal effort.

Key findings

- Building can cost $21M-$38M. Estimates reflect not only technology development, but also the content, coaching methodologies, and compliance infrastructure required to support an effective program.

- Time may be the bigger hurdle. No workplace financial wellness platform with a public funding history reached maturity in less than a decade.

- Expertise, not budget, is the real barrier. Effective programs require specialized knowledge in behavioral finance, coaching, and financial education, alongside benefits and technology expertise.

- Even the experts buy. Leading financial wellness providers have used acquisitions to add capabilities rather than building every component themselves internally.

- Deep internal expertise narrows the gap, but doesn't close it. Organizations with strong capabilities across personal finance, benefits, and software development may reduce costs to an estimated $14M-$25M, but significant investment is still required.

- A financial wellness program is never finished. Tax laws, retirement plan contribution limits, and employee benefits offerings change regularly, so content, coaching guidance, and compliance reviews all need ongoing updates. Organizations that build their own program take on that maintenance indefinitely.

The report is clear that purchasing a financial wellness solution does not eliminate the employer's role. Programs deliver results when organizations commit to them, promote them and give employees time and encouragement to use them. It also identifies the narrow set of organizations for which building internally is the right call: those with deep, sustained expertise across personal finance, employee benefits and software, and the resources to maintain and update a program that is never finished.

"Organizations tend to do their best work when they invest their own time and talent in what they exist to do, and lean on specialists for the rest," adds Davidson. "Financial wellness may not be most employers' core business, but their people are, and when they pair proven expertise with genuine commitment, they can change their employees' financial futures."

For employers weighing the decision, the report recommends a straightforward next step: ask a provider's consulting team what the same capability costs to buy and compare the two figures.

The full white paper is available at Build or Buy: What It Costs to Create a Financial Wellness Benefit - Financial Finesse.

Methodology: Development cost figures are Financial Finesse estimates derived from public venture financing disclosures and published software industry operating expense benchmarks, not verified company financial statements. Employer sourcing data is from the 2025 EBRI Financial Wellbeing Employer Survey of benefits decision makers at companies with 500 or more employees (n=406 in 2025). Financial Finesse is among the organizations that provided funding for the survey. Replication cost ratios are from Mansfield, Schwartz and Wagner, The Economic Journal (1981), a study of manufactured products, applied as the closest available benchmark rather than a direct measure of software and services development.

About Financial Finesse

Financial Finesse is the leading independent global provider of unbiased financial coaching as an employee benefit, driving measurable improvements in employee financial wellness and proven employer ROI. Employees receive unlimited access to certified financial coaches, CFP® professionals or in-country equivalents, and AI-powered guidance that expands reach and personalization with trusted human oversight at every step.

Serving more than 20,000 organizations and reaching millions of employees worldwide through a single integrated platform, Financial Finesse delivers localized experiences tailored to each employee's country, language, culture, financial system, and benefits. The result: reduced financial stress, seamless scalability for employers, and a benefit employees trust, value, and actively use. Learn more at financialfinesse.com.

Media Contact

Danielle Encinas, Marcom Manager | [email protected] | 909-217-1749

SOURCE Financial Finesse

Share this article

Copenhagen Infrastructure Partners invests in Via Verde, Italian biomethane platform

The investment in the Via Verde platform marks Copenhagen Infrastructure Partners' (CIP) entry into the Italian biomethane market, with a development pipeline of 20 biomethane projects.

COPENHAGEN, Denmark, Oct. 7, 2026 /PRNewswire/ -- Copenhagen Infrastructure Partners (CIP), through its Advanced Bioenergy Fund II (ABF II), has reached final investment decision (FID) on Via Verde, an Italian biomethane platform. ABF II invests primarily in the development, construction, and operation of biogas plants across Europe, converting agricultural waste and other sustainable feedstock into biomethane.

Via Verde represents ABF II's first investment and marks CIP's entry into the Italian biomethane market. The investment will create local jobs and supply domestically produced biomethane, which will replace imported fossil gas, supporting both Italy's energy independence and decarbonisation efforts.

Via Verde comprises a development pipeline of 20 projects strategically located across multiple regions of Italy, including Lombardy, Abruzzo, and Campania. Each plant is expected to process approximately 60,000 to 100,000 tonnes of agricultural waste annually.

Once the 20 projects are fully operational, the Via Verde platform will deliver approximately 1 TWh of biomethane annually, equivalent to the annual gas consumption of around 60,000 Italian households.

Andreas F. Brandt, Partner at CIP, says of the new investment: "Via Verde marks our entry into one of Europe's most attractive biomethane markets, giving us a strong foothold as Italy scales towards its 2030 biomethane targets. CIP will leverage its advanced bioenergy expertise to support Via Verde's experienced local team and substantial project pipeline, laying a strong foundation for long-term growth. We believe biomethane will play a key role in strengthening Italy's energy independence and supporting its transition to a lower-carbon energy system."

Supported by favourable market fundamentals and policy support mechanisms, Via Verde is expected to establish an early at-scale position in the Italian biomethane market and support the expansion of domestic renewable gas production.

Notes to Editors

Media Contact

E-mail: [email protected] / M: +45 2844 7756

About Advanced Bioenergy Fund II

Copenhagen Infrastructure Advanced Bioenergy Fund II (CI ABF II) started fundraising in summer 2025. The fund leverages the seed portfolio and the in-house capabilities that CIP has built over the past four years for CI ABF I, providing a financially attractive product to our investors, both in terms of returns and diversified risks.

About Copenhagen Infrastructure Partners

Founded in 2012, Copenhagen Infrastructure Partners P/S (CIP) is a global fund manager and leading investor in energy infrastructure.

Through its funds, CIP invests in power generation (solar and wind), energy storage, transmission and distribution, advanced bioenergy, low-carbon fuels and carbon capture.

With 15 funds currently under management, CIP is trusted by over 200 of the world's largest and most sophisticated institutions. CIP has projects in more than 30 countries, with presence on the ground through a network of more than 2,300 professionals.

For more information, visit www.cip.com.

Legal disclaimer

This release does not constitute an offer to sell or the solicitation of an offer to purchase any security. Any investment involves substantial risks including complete loss of capital. There can be no assurance that CIP will be able to implement the strategy described herein or, if implemented, that it will lead to successful results. Similarly, there can be no assurance that CIP will be able to maintain the advantages discussed herein over time or outperform third parties or the financial markets generally.

Certain information contained herein constitutes "forward-looking statements," which can be identified by the use of terms such as "may," "will," "expects," "intends," "plans," "believes," "estimates" or comparable terminology.

Forward-looking statements are subject to a number of known and unknown risks and uncertainties, including, without limitation, changes in economic conditions, political changes, legal and regulatory requirements, interest rate fluctuations, as well as changes in markets, prospects and competition. There can be no assurance that historical trends will continue. Some of the views expressed herein are the opinions of CIP and should not be construed as absolute statements and are subject to change without notice.

This information was brought to you by Cision http://news.cision.com.

Share this article

NX Group and JAL Launch Intra-Asia/North America-Asia Transport Partnership

- Building Transport Network with Large Freighter Aircraft to Meet Growing Demand for AI- and Semiconductor-related Cargo Transportation -

TOKYO, Oct. 7, 2026 /PRNewswire/ -- NIPPON EXPRESS HOLDINGS, INC. ("NX Group") and Japan Airlines Co., Ltd. ("JAL") have launched a transport partnership covering intra-Asia and North America-Asia routes, utilizing a Boeing 747 freighter ("747F") secured by JAL through cooperation with its partners. The service operates on a round-trip circuit originating in Los Angeles and routing via Narita, Taipei (Taoyuan), Singapore and Narita before returning to Los Angeles, responding to robust demand between North America and Asia as well as within Asia. The first flight departed Los Angeles on Saturday, October 3, 2026. The service is available with one flight per week in 2026, and both companies will continue to pursue further network expansion going forward.

Logo: https://drive.google.com/file/d/1dqm0cxpYamnvMUra1AGXMuGlX932Z353/view?usp=drive_link

Image1: https://drive.google.com/file/d/1R89Wm4ltRkyCoIhdG9mICMS76uZKaiem/view?usp=drive_link

Service Features

-Securing scarce large-freighter capacity within Asia

Demand for AI- and semiconductor-related cargo is currently very strong, particularly between Tokyo, Taipei and Singapore, yet few airlines operate large freighters within Asia, leaving shippers with limited options. By operating the Narita-Taipei-Singapore-Narita route with a 747F offering a maximum payload of approximately 100 tons, this service provides a distinctive, high-value-added offering that creates a vital network within Asia.

-Strengthening transport network linking North America and Asia

Because cargo can be loaded and unloaded at each port of call on the circuit route, the service enables the design of diverse transport routes and efficient transport operations, flexibly meeting cargo transport needs between North America (including Latin America beyond) and Asia.

-Meeting demand for rapidly growing high-value-added cargo

Leveraging the unique capabilities of large freighter aircraft, the service accommodates transport demand for oversized and heavy cargo such as server racks and data center-related equipment, as well as high-value-added cargo, which is increasing alongside the spread of generative AI and expanding investment in digital infrastructure.

Through this partnership, the two companies will secure stable and flexible air transport capacity, deliver optimal transport services that meet diverse needs and pursue sustainable growth as part of the logistics infrastructure.

Image2: https://drive.google.com/file/d/1tmYm1GzYQ6IGhiXI7VHqjRoOMFXNR41q/view?usp=drive_link

Comments from Representatives

NIPPON EXPRESS HOLDINGS, INC.

Satoshi Otsuji, Senior Managing Executive Officer, President of Global Business Headquarters

"Through this partnership, the NX Group will strengthen its ability to provide more stable and flexible transport solutions in response to increasingly sophisticated and diverse air transport needs. Building on our many years of cooperation with JAL, we will further expand our international air cargo network utilizing large freighter aircraft, contributing to the stability of our customers' supply chains and to their business growth."

Japan Airlines Co., Ltd.

Yuichiro Kito, Executive Officer, Senior Vice President - Cargo and Mail

"This new partnership further strengthens the long-standing relationship between JAL and the NX Group. In addition to our passenger flights and our own freighter network, this partnership with NX will bring large freighter service to the U.S. West Coast for the first time. We will expand our air cargo network in rapidly growing markets and deliver JALCARGO's high-quality cargo handling services to even more customers."

About the NX Group: 

https://drive.google.com/file/d/1mbvBL6C8THZNrR5LREgGeafNkEdaAmV-/view?usp=drive_link

NX Group official website: https://www.nipponexpress.com/

NX Group's official LinkedIn account: https://www.linkedin.com/company/nippon-express-group/

SOURCE NIPPON EXPRESS HOLDINGS, INC. and Japan Airlines Co., Ltd.

Share this article

OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration

LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain penetration of tyrosine kinase inhibitors (TKIs).

OB-001 is a highly selective and effective inhibitor of two key efflux pumps (P-gp and BCRP), which are present both on the blood-brain barrier and on tumour cells. The product is being developed as a once-daily oral tablet, which will be used in combination with a number of gold standard oncology treatments in order to optimise their efficacy.

In perfused-brain mouse studies, OB-001 pretreatment significantly raised brain exposure of four gold standard kinase inhibitors – whilst systemic (plasma) exposure remained broadly unchanged. Data presented at AACR 2026 demonstrated that OB-001 could increase the brain exposure of osimertinib by almost 400% with minimal systemic changes[1],[2]. Based on a translational PK-PD-TGI model for osimertinib, this increase is projected to deliver a step-change in CNS progression-free survival for EGFRm NSCLC patients. The improved control of brain metastases is still a major area of unmet need in NSCLC and breast cancer.

The same efflux pumps have also been identified as a key resistance mechanism impacting ADCs – with the over-expression of these pumps leading to reduced payload concentrations in the tumour. Preclinical work using a bidirectional transporter assay demonstrated that OB-001 reduces efflux for several leading payloads, including SN-38 (e.g. sacituzumab govitecan, Trodelvy®), DM4 (e.g. mirvetuximab soravtansine, Elahere®) and DXd (e.g. trastuzumab deruxtecan, Enhertu®).

Plans are currently underway to move into a parallel clinical trial programme to generate POC data in combination with osimertinib, and also evaluate T-DXd re-sensitisation.

"This is a critical milestone for our team, and we are now well positioned to initiate our clinical plans with OB-001" said Jim Millen, Chief Executive Officer for OncoBayes. "OB-001 is on track to become a first-in-class drug with broad potential as a simple, oral adjunct to a range of blockbuster oncology therapies. This is truly a pipeline in a product opportunity."

References:

1. AACR2026 Abstract 5873. 1 April 2026; 86 (7_Supplement): 5873. https://doi.org/10.1158/1538-7445.AM2026-5873.

2. Cancer Research Communications 1 May 2026; 6 (5): 1213–1219. https://doi.org/10.1158/2767-9764.CRC-25-0553.

SOURCE OncoBayes

Share this article

Market Logic's DeepSights MCP scales market insights reach and business impact through enterprise-wide AI workflows

DeepSights MCP, now generally available, connects an expert market intelligence AI to Microsoft Copilot, ChatGPT, Claude and custom agents, so everyday AI work draws on accurate, cited market evidence

BERLIN, Oct. 7, 2026 /PRNewswire/ -- Market Logic Software, the company behind DeepSights. the leading AI market intelligence platform, today announced the general availability of DeepSights MCP. The Model Context Protocol (MCP) connection makes DeepSights the expert source that enterprise AI assistants and agents consult whenever a question depends on knowledge of the market. It extends the reach of each customer's curated market knowledge from the insights team to every employee and every AI workflow in the business.

Large organizations invest tens of millions every year in consumer and market research. The return on that investment depends on how widely, and how often, the resulting insights shape business decisions. Connecting trusted market intelligence to the rapid spread of enterprise AI assistants, from Microsoft Copilot to ChatGPT and Claude, creates a golden opportunity to extend insights impact to a new level.

Once the DeepSights MCP is in place, AI assistants call on DeepSights as a matter of course to answer questions about customers, categories and competitors. Similarly, automated, multi-step workflows proactively draw expert input on market from DeepSights before handing off to other agents to complete tasks.

The connection also addresses the growing risk of business decisions being fed by incomplete or misleading information by generic AIs rather than specialized AI. DeepSights works the way an insights expert does to provide an accurate, evidence-backed view of the market. It analyzes information proactively, separating what is relevant from noise. DeepSights works only on trusted data and cites its references in every answer.

"Your AI knows your company. DeepSights knows your market," said Olaf Lenzmann, Chief Innovation and Product Officer at Market Logic. "Our customers have spent years and significant budgets building a unique understanding of their consumers and markets. Adding DeepSights at the market intelligence layer for enterprise AI ensures that competitive advantage is seized on and integral to decision making processes. The DeepSights MCP will make it easier than ever for trusted, evidence-backed market intelligence to flow freely through the organization."

Establishing DeepSights as the trusted market intelligence layer for all AI workflows also gives insights and IT teams one central way to govern and secure the knowledge that creates their unique market understanding. Insights team continues to decide which sources are trusted. User permissions in DeepSights controlling which sources an individual has access to are carried through by the MCP into information shared through other AI assistants. Because the connection is built on the open Model Context Protocol (MCP), the same governed layer serves every assistant and agent the company adopts.

DeepSights MCP is generally available to DeepSights customers today. It works with Microsoft Copilot, ChatGPT, Claude, Glean and other assistants and agents that support the Model Context Protocol. For more information, visit www.marketlogicsoftware.com.

About Market Logic Software

Market Logic Software is a provider of pioneering market intelligence and insights solutions. Its AI-enabled platform, DeepSights, helps organizations make research and market intelligence available to decisionmakers across the enterprise at scale and speed. For more than 15 years, Market Logic has worked with consumer-focused brands around the world to support insights-driven decision-making. Customers include Vodafone, Bayer and Philips. More information is available at https://marketlogicsoftware.com.

SOURCE Market Logic Software AG

Share this article

LG CNS Showcases Pharma-Specific Manufacturing AX at World's Largest Pharma-Biotech Show

- Participates in CPHI Milan 2026, Expanding Manufacturing AX Reach in Pharma

- Showcasing key solutions for factory design, production operations, and quality management using the theme "Autonomous Factory in Pharma"

SEOUL, South Korea and MILAN, Oct. 7, 2026 /PRNewswire/ -- LG CNS, a leading AI Transformation company in Korea, is expanding its manufacturing AX business with a showcase of pharma-specific smart factory technologies at CPHI Milan 2026, the world's largest pharmaceutical and biotech exhibition.

The Convention on Pharmaceutical Ingredients (CPHI) is a global pharma and biotech trade show held at various global venues throughout the year, including the United States, Europe, Asia, and the Middle East. The Milan show is CPHI's flagship event, drawing around 60,000 visitors and roughly 3,000 companies from more than 160 countries. It is widely regarded as the premier stage on which the latest technologies and trends of the global pharma and biotech industry converge. LG CNS is the only Korean company participating in the newly created "AI & Tech" zone this year.

The theme of LG CNS's booth is Autonomous Factory in Pharma and is designed around the introduction of three smart factory solutions connecting factory design, production operations, and quality management. Pharma and biotech companies building or expanding production facilities can adopt these solutions across the entire process, from factory construction through ongoing operations.

For the factory design stage, LG CNS presents Factova Worldworks, a digital twin-based virtual validation simulator that recreates the actual factory in a virtual space. It models the factory layout in 3D to review the optimal placement of pharmaceutical manufacturing equipment, the routes that workers will take within the planned factory, and the path along which raw materials are to be transferred. Pharmaceutical factories separate zones such as cleanrooms and production areas to prevent raw material contamination. Worker access permissions also differ by zone, so planning their routes carefully in advance is more essential than in general manufacturing factories.

Factova Control is a data standardization and equipment control solution for the production operations stage. It automatically converts process data such as raw material ID numbers and formulations into a unified format, unit, and notation so that every manufacturing step works from consistent data. This lets customers respond immediately when adding new equipment or changing process workflows. The solution also detects equipment anomalies and predicts failures, using AI to analyze electrical current, temperature, and vibration data in real time to flag early warning signs.

The quality management solution analyzes data such as production volume, raw material temperature changes, and equipment operation history to check for product quality issues. It also supports everything from root-cause investigations to follow-up actions when problems are identified. Notably, when it detects an anomaly midway through a process, it immediately calculates alternatives to resolve the issue and then applies them to the next production step, proactively preventing defective products.

An AI agent trained on quality data also drafts the Annual Product Quality Review (APQR). Pharma and biotech companies conduct annual quality reviews to comply with each country's Good Manufacturing Practice (GMP) regulations and document the results in the APQR. Previously, staff collected, analyzed, and verified the required data by hand, a process that could take months. LG CNS has automated the entire process with AI, cutting the time required by more than 90%.

"The manufacturing AX solutions we are showcasing at this exhibition are tailored to pharma so we can support our pharma and biotech customers with intelligent automation across the entire process, from factory design to quality management," said Eddie Jang, Head of the Chemical/Battery Division at LG CNS. "As a turnkey provider covering every area of manufacturing, we will continue to use our advanced solutions to address the challenges of developing pharmaceutical manufacturing sites, which demand high precision and strict quality standards, and help customers produce medicines in a more automated and efficient way."

About LG CNS

LG CNS is a leading Korean AX (AI Transformation) company that continues to pioneer various emerging technologies, including AI, robotics, cloud computing, data center, and smart engineering, encompassing smart factories and smart logistics, as well as digital marketing. The company also leads the market through innovative system integration (SI) and system management (SM) capabilities across finance, manufacturing, the public sector, and various other industries. For more information, please visit https://www.lgcns.com.

Share this article

NEW DELHI, Oct. 7, 2026 /PRNewswire/ -- Fibocom showcases its MGB Series GNSS portfolio at India Mobile Congress (IMC) 2026, featuring MGB180, MGB280 and MGB390. Spanning cost-efficient single-frequency positioning to dual-frequency and RTK-enabled high-accuracy positioning, the series offers flexible options for IoT devices with different design priorities, including cost, power consumption, positioning accuracy and regional satellite compatibility.

MGB180 and MGB280 address mainstream single-frequency GNSS requirements, supporting GPS, BDS, GLONASS, Galileo and QZSS. Both integrate AGNSS and provide 96 tracking channels. MGB180 targets highly cost-sensitive tracking devices, combining compact integration with low-power operation. MGB280 further balances positioning performance and power efficiency, with strengths in fast startup, reacquisition and cellular coexistence for applications such as asset tracking, fleet management and vehicle telematics.

For more demanding positioning requirements, MGB390 extends the series with dual-frequency GNSS and 180 tracking channels. The MGB390-AR supports RTK high-accuracy positioning, with specified horizontal accuracy of 1 cm + 1 ppm. The MGB390-A supports NavIC (IRNSS), India's regional navigation satellite system, strengthening local applicability for the Indian market.

"As India's IoT ecosystem continues to grow, customers are looking for reliable technology partners that can support their journey from product development to large-scale deployment," said Kony Li, General Manager of Fibocom MTC Business Unit. "With the MGB Series, Fibocom provides flexible GNSS solutions covering different levels of cost, power consumption and positioning performance, helping local customers accelerate the development and commercialization of IoT devices."

MGB180, MGB280 and MGB390 are all in mass production. Fibocom continues to work with customers and ecosystem partners in India to accelerate product integration and commercialization across location-enabled IoT devices.

About Fibocom

Fibocom, founded in 1999, provides wireless communication and AI solutions through integrated hardware and software capabilities. Its portfolio spans cellular communication, AI, automotive and GNSS modules, supporting intelligent connectivity across industries including transportation, energy, retail and robotics.

SOURCE Fibocom

Share this article

Half-day complimentary workshop will provide Santa Barbara County nonprofit staff and board members with strategies to build media visibility and earn meaningful coverage

SANTA BARBARA, Calif., Oct. 7, 2026 /PRNewswire/ -- Marketing Maven CEO and president Lindsey Carnett will lead "Building Media Visibility For Your Nonprofit: PR Strategies That Get Results," an in-person workshop presented by California Lutheran University's Center for Nonprofit Leadership with support from the Santa Barbara Foundation on Wednesday, October 7, 2026 from 9 a.m. to noon at the Santa Barbara Foundation's South County office.

Through the generous support of the Santa Barbara Foundation, the workshop is offered free of charge to nonprofit professionals and board members serving communities throughout Santa Barbara County. The interactive, three-part workshop is designed to help participants develop the skills and strategies needed to identify newsworthy stories, craft compelling messages and build relationships with relevant media outlets.

"Every nonprofit has stories worth telling, but earning meaningful media coverage requires knowing how to identify those stories and communicate why they matter," said Carnett. "My goal is for participants to leave with practical PR strategies they can immediately put to work to strengthen visibility, build credibility and create greater awareness of their organizations and missions."

During the workshop, participants will develop potential story ideas, refine media pitches and practice identifying appropriate media targets while receiving feedback in a collaborative environment. Attendees will also learn how to repurpose earned media coverage across other marketing channels to extend its value and support broader organizational objectives.

The workshop will explore how strategic earned media can help nonprofits strengthen donor engagement, increase community awareness, support board recruitment and engagement and enhance organizational reputation. A panel of local nonprofit leaders who have successfully generated media coverage will share their experiences, practical strategies and lessons learned, providing attendees with real-world insights they can apply within their own organizations.

Carnett is a marketing and public relations professional with more than two decades of industry experience. As CEO and president of Marketing Maven, a research-driven integrated marketing and public relations agency, she has advised organizations on public relations, reputation management, social media, search engine optimization, GEO and other integrated communications strategies. Carnett also serves as a faculty lecturer for Cal Lutheran's Center for Nonprofit Leadership and is an alumna of the university.

"Building Media Visibility For Your Nonprofit: PR Strategies That Get Results" will take place Wednesday, October 7, 2026, from 9 a.m. to noon at the Santa Barbara Foundation South County office, 1111 Chapala Street, Suite 200, Santa Barbara. Additional information and registration are available through Cal Lutheran's Center for Nonprofit Leadership: Building Media Visibility For Your Nonprofit: PR Strategies That Get Results | Center for Nonprofit Leadership

To attend, please reach out to Sophia Coffaro at [email protected] or Brewster King at [email protected].

About the Center for Nonprofit Leadership

As the only management training center of its kind in the region, the Center for Nonprofit Leadership provides practical and affordable professional development opportunities for nonprofit leaders serving Ventura and Santa Barbara Counties. The CNL is committed to equipping nonprofit leaders with data-driven resources and training to support long-term success. To learn more, visit CalLutheran.edu/CNL or contact [email protected]/.

About Santa Barbara Foundation

Founded in 1928, the Santa Barbara Foundation actively connects donors, nonprofits, government, businesses and the people of Santa Barbara County to take on the most challenging needs facing our region's communities. Recognizing that its work depends on the strength of the social sector, the Foundation is committed to the health and vitality of local nonprofits. Knowing that together we can do more, the Foundation mobilizes charitable giving and connects their expertise to that of donors, nonprofits and residents to create meaningful impact on the communities of our county. SBFoundation.org.   

About Lindsey Carnett

Lindsey Carnett is a marketing and public relations professional who developed The Marketing Maven Method to simplify marketing by empowering leaders to make data-driven marketing decisions. Lindsey is the CEO of Marketing Maven, a research, digital and PR firm headquartered in Ventura County, and author of the recent book, The Marketing Maven Method: Secrets of a Maven.

A two-time honoree of Inc. 5000 Fastest Growing Independently Owned Companies in America, as well as an Entrepreneur 360 Most Entrepreneurial Companies in America award recipient, Lindsey has taken her business expertise global to enlighten marketing peers and business leaders about best practices in using PR to drive engagement, improve organic SEO, and grow a positive online reputation.

Having spoken at high profile national marketing and consumer products conferences and guest lectured at universities, Carnett has gained the reputation as an expert in the field of marketing and public relations. Her areas of specialties include: Public Relations, Social Media, Reputation Management, Direct Response Marketing, U.S. product launches, SEO, GEO, Event PR, and Spanish Media. To learn more about Lindsey, visit www.LindseyCarnett.com.

About Marketing Maven:

With offices in Camarillo, Los Angeles, and New York City, Marketing Maven is a full-service marketing and communications agency. With origins in direct response public relations, Marketing Maven has developed into a premier voice in brand strategy, social media, innovative media relations, market research, Hispanic marketing, digital advertising and search engine optimization (SEO/GEO). Marketing Maven leads the industry in utilizing advanced metrics to measure their clients' marketing reach and providing competitive analysis unparalleled in the industry. For additional information about Marketing Maven, visit http://www.MarketingMaven.com.

Contact: [email protected]

SOURCE Marketing Maven Public Relations, Inc.

Share this article

Roche Diagnostics delivers laboratory equipment to support Ebola testing in DRC

- Roche Diagnostics has provided two molecular testing instruments to Institut National de Santé Publique (INSP) to support Ebola testing capacity in the DRC.

- Roche will preconfigure the instruments and train local laboratory technicians before deploying them to Bunia.

- INSP will conduct local validation of the Bundibugyo virus, after which Roche anticipates further tests could be shipped and additional instruments deployed

JOHANNESBURG, Oct. 7, 2026 /PRNewswire/ -- As the outbreak of Ebola disease caused by Bundibugyo virus continues in the Democratic Republic of Congo (DRC), demand for testing is exceeding current available laboratory capacity, and strategic public-private partnerships are powering rapid testing and a more effective disease response. As a result, Roche Diagnostics has committed to reinforcing local laboratory testing capacity and training laboratory staff to boost essential testing capacity.1

Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique (INSP), which is supporting the DRC's Ministry of Health-led Ebola response. Roche will preconfigure the Light cycler and Magna Pure instruments, and local laboratory technicians will receive training before deploying the equipment to Bunia for validation testing.

"Outbreak response depends on having the right testing capability available where it is needed," said Johan Descombes, General Manager, Francophone West Africa. "By working with the INSP to provide equipment, training and support for local validation, Roche Diagnostics is helping to expand the laboratory capacity available to the dedicated responders in the DRC. At this critical time, local expertise is crucial to fighting the outbreak, and this is an important step forward in expanding testing capacity to help respond to local needs."

The delivery follows Roche's announcement in June that it had developed a Research Use Only molecular PCR test targeting Bundibugyo virus. With the instruments now in the DRC, this partnership aims to build local testing capacity and secure the regulatory validation needed before shipping further tests.

As of 28 September 2026, UN Health Authority data reported 8,067 confirmed cases and 3,901 deaths, putting the case fatality rate at 48.4% across 60 health zones in six provinces. WHO assessed the risk in the DRC as very high and confirmed that the outbreak remains a public health emergency of international concern.

Rapid, reliable laboratory testing is vital to outbreak response, supporting case detection, surveillance, and efforts to interrupt transmission. WHO's temporary recommendations for the DRC emphasise strengthened surveillance, case detection and investigation as part of the ongoing efforts to curb the current outbreak.3

"The delivery of these instruments is an important step, but the work continues," concluded Descombes. "As validation progresses, we are committed to working alongside the INSP and local laboratory teams to understand where further support can make the greatest difference. We aim to contribute to testing capacity that can respond to this outbreak and strengthen preparedness for future outbreaks and pandemics."

Once validation of the Research Use Only tests is complete, Roche anticipates deploying additional instruments and expediting delivery of more tests to support the response.

About Roche

Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions.

Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them.

Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market.

For more information, please visit www.roche.com.

Bundibugyo virus Research Use Only test is for research use only. Not for use in diagnostic procedures.

All trademarks used or mentioned in this release are protected by law.

References

[1] CDC Ebola Outbreak: Current Situation. 07 September 2026: https://www.cdc.gov/ebola/situation-summary/index.html

[2] World Health Organization. Ebola disease caused by Bundibugyo virus – Democratic Republic of the Congo. Disease Outbreak News. 28 August 2026. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON616

[3] World Health Organization. Second meeting of the IHR Emergency Committee on the epidemic of Ebola Bundibugyo virus disease in the Democratic Republic of the Congo – Temporary recommendations. 24 August 2026. https://www.who.int/news/item/24-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo-temporary-recommendations

For further information, please contact

Katlego Ledimo, Africa Communications

Phone: +27 726 151 941  

e-Mail: [email protected] 

Kathryn Ager, Diagnostics Global Communications

Phone: +44 77 745 115 046

e-Mail: [email protected]

Share this article